Scholar Rock announced that the first participants were dosed in the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab, an investigational, highly selective myostatin inhibitor, to preserve lean muscle mass in individuals living with obesity and on background therapy of a GLP-1 receptor agonist, GLP-1 RA. The trial will also evaluate the effects of apitegromab on the durability of weight loss upon withdrawal of GLP-1 RA therapy. The results from this trial will inform the development of SRK-439, a novel investigational selective myostatin inhibitor optimized for the treatment of cardiometabolic disorders, including obesity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- Scholar Rock price target raised to $31 from $29 at BMO Capital
- Scholar Rock Unveils Promising Cancer Trial Results at ASCO 2024
- Scholar Rock presents new deata from SRK-181 Phase 1 trial at ASCO
- Scholar Rock participates in a conference call with JPMorgan
- Scholar Rock initiates EMBRAZE clinical trial of apitegromab in obesity
Questions or Comments about the article? Write to editor@tipranks.com